ABC | Volume 111, Nº3, September 2018

Original Article Marino et al Adiponectin and IVUS-VH Coronary Plaque Characteristics Arq Bras Cardiol. 2018; 111(3):345-353 Table 1 – Baseline characteristics Total (n = 570) ACS patients (n = 309) SAP patients (n = 261) Patient characteristics Age, years (mean±SD) 61.5 ± 11.4 59.7 ± 11.9 63.6 ± 10.3 Men, n (%) 430 (75.4) 227 (73.5) 203 (77.8) Diabetes Mellitus, n (%) 99 (17.4) 40 (12.9) 59 (22.6) Hypertension, n (%) 295 (51.8) 134 (43.4) 161 (61.7) Hypercholesterolemia, n (%) 317 (55.6) 137 (44.3) 180 (69.0) Smoking, n (%) 164 (28.8) 115 (37.2) 49 (18.8) Positive family history, n (%) 293 (51.5) 140 (45.3) 153 (58.6) Previous MI, n (%) 184 (32.3) 80 (25.9) 104 (58.6) Previous PCI, n (%) 185 (32.5) 57 (18.4) 128 (49.0) Previous CABG, n (%) 18 (3.2) 7 (2.3) 11 (4.2) Previous stroke, n (%) 23 (4.0) 10 (3.2) 13 (5.0) Peripheral artery disease, n (%) 36 (6.3) 12 (3.9) 24 (9.2) History of renal insufficiency (%) 32 (5.6) 13 (4.2) 19 (7.3) History of heart failure, n (%) 19 (3.3) 6 (1.9) 13 (5.0) Procedural characteristics Indication for coronary angiography Acute coronary syndrome, n (%) 309 (54.2) 309 (100) 0 (0) Myocardial infarction, n (%) 159 (27.9) 159 (51.5) 0 (0) Unstable angina pectoris, n (%) 150 (26.3) 150 (48.5) 0 (0) Stable angina pectoris, n (%) 261 (45.8) 0 (0) 261 (100) Coronary artery disease No significant stenosis, n (%) 42 (7.4) 18 (5.8) 24 (9.2) 1-vessel disease, n (%) 301 (52.8) 168 (54.4) 133 (51.0) 2-vessel disease, n (%) 166 (29.1) 88 (28.5) 78 (29.9) 3-vessel disease, n (%) 61 (10.7) 35 (11.3) 26 (10.0) PCI performed, n (%) 501 (87.9) 287 (92.9) 214 (82.0) IVUS characteristics Segment length (mm), median (IQR) 44.1 (33.7-55.4) 43.9 [32.9-54.1] 44.8 [34.2-57.2] Plaque burden (%), median (IQR) 39.2 (30.0-46.4) 37.2 [28.0-45.5] 40.2 [31.8-47.8] Presence lesion with MLA ≤ 4.0mm 2 176 (30.9) 88 (28.7) 88 (33.7) Presence of VH-TCFA, n (%) 239 (41.9) 140 (45.5) 99 (37.9) Presence of VH-TCFA with PB ≥ 70%, n (%) 69 (12.1) 32 (10.4) 37 (14.2) Serum biomarker concentrations C-reactive protein (mg/L), median [IQR] 2.1 [0.8-5.3] 2.8 [1.1-7.0] 1.5[0.6-3.1] Adiponectin (μg/mL) median [IQR] 2.8 [1.9-4.0] 2.9 [1.8-4.1] 2.9 [1.9-3.9] ACS: acute coronary syndrome; SAP: stable angina pectoris; SD: standard deviation; MI: myocardial infarction; PCI: percutaneous coronary intervention; CABG: coronary artery bypass grafting; IVUS: intravascular ultrasound; IQR: interquartile range; MLA: minimal luminal area; VH-TCFA: virtual histology thin-cap fibroatheroma; PB: plaque burden. characterized by a marked systemic pro-inflammatory state and endothelial dysfunction, adiponectin levels increase as an attempt to counter-regulate or compensate for this systemic inflammation. Consequently, the protective effects of adiponectin are superseded by the underlying disease. 25 In a cohort of 981 patients with stable ischemic heart disease, with average follow-up of 7.1 years, an association was found between higher adiponectin and adverse cardiovascular events (death, heart failure), but after adjustment for cardiac disease severity, the association was no longer statically significant. 24 348